

Leverett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	3.0	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	11	8.5	130.0	(64.8-232.7)	Female	0	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.3	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	3.4	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	1.0	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	12	13.4	89.6	(46.3-156.6)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.1	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.3	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.7	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.0	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	27	42.0	64.2	(42.3-93.5)
Male	1	1.0	nc	(nc-nc)	Female	28	27.5	101.9	(67.7-147.2)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	2	5.7	nc	(nc-nc)					
Female	3	3.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lexington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	31	42.6	72.8	(49.4-103.3)	Male	41	26.0	157.4	(113.0-213.6)
Female	12	16.0	75.0	(38.7-130.9)	Female	29	20.8	139.7	(93.5-200.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	7.3	178.4	(94.9-305.0)	Male	7	7.2	96.9	(38.8-199.7)
Female	3	6.6	nc	(nc-nc)	Female	9	6.1	148.5	(67.7-281.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	1.3	nc	(nc-nc)	Male	24	23.2	103.3	(66.1-153.6)
Female	184	156.8	117.4	(101.0-135.6)	Female	22	20.4	107.8	(67.5-163.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	5.3	nc	(nc-nc)	Male	9	16.2	55.6	(25.4-105.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	37	48.6	76.1	(53.5-104.8)	Female	13	14.5	89.6	(47.6-153.2)
Female	41	52.5	78.0	(56.0-105.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	13.6	66.3	(30.3-125.9)
Male	4	10.8	nc	(nc-nc)	Female	16	15.9	100.7	(57.5-163.6)
Female	5	3.3	149.4	(48.1-348.6)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	142	152.0	93.4	(78.7-110.1)
Male	2	2.5	nc	(nc-nc)	<u>Stomach</u>				
Female	1	2.3	nc	(nc-nc)	Male	6	9.7	61.8	(22.6-134.4)
<u>Kidney & Renal Pelvis</u>					Female	6	6.4	94.2	(34.4-205.1)
Male	17	21.3	79.9	(46.5-128.0)	<u>Testis</u>				
Female	5	13.1	38.3	(12.3-89.3)	Male	2	3.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	6.2	nc	(nc-nc)	Male	14	8.0	174.5	(95.3-292.8)
Female	0	1.9	nc	(nc-nc)	Female	34	25.1	135.7	(93.9-189.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	21	15.3	137.1	(84.8-209.6)	Female	30	35.8	83.9	(56.6-119.8)
Female	16	11.9	134.2	(76.7-218.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	473	546.7	86.5	(78.9-94.7)
Male	6	12.3	48.8	(17.8-106.2)	Female	528	553.5	95.4	(87.4-103.9)
Female	3	4.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	47	76.3	61.6	(45.3-81.9)					
Female	49	81.0	60.5	(44.8-80.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leyden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.7	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	3.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	1.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	3.7	186.7	(74.8-384.7)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lincoln

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	9.3	53.8	(17.3-125.6)	Male	3	5.7	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	5	3.9	128.7	(41.5-300.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.7	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	7	5.2	135.3	(54.2-278.8)
Female	31	28.7	108.1	(73.4-153.4)	Female	3	3.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.1	nc	(nc-nc)	Male	1	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	10.8	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
Female	4	8.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	3.0	nc	(nc-nc)
Male	0	2.3	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	38	30.5	124.7	(88.2-171.1)
Male	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.0	nc	(nc-nc)
Male	5	4.5	110.3	(35.6-257.5)	<u>Testis</u>				
Female	2	2.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.3	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	5	5.4	93.1	(30.0-217.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.6	nc	(nc-nc)	Female	5	6.6	75.6	(24.4-176.4)
Female	4	2.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	83	116.9	71.0	(56.5-88.0)
Male	0	2.6	nc	(nc-nc)	Female	85	97.1	87.6	(69.9-108.3)
Female	0	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	6	15.6	38.4	(14.0-83.5)					
Female	10	13.7	73.2	(35.0-134.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Littleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	9.3	75.0	(30.1-154.6)	Male	8	6.3	126.7	(54.6-249.7)
Female	1	3.3	nc	(nc-nc)	Female	2	5.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.9	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.6	89.4	(28.8-208.5)
Female	30	36.7	81.6	(55.1-116.5)	Female	6	4.5	134.7	(49.2-293.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	1	4.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	11.2	98.6	(49.2-176.5)	Female	3	3.3	nc	(nc-nc)
Female	12	11.0	109.4	(56.5-191.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	3.1	nc	(nc-nc)
Male	1	2.6	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	38	37.5	101.5	(71.8-139.3)
Male	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.3	nc	(nc-nc)
Male	6	5.3	112.7	(41.1-245.2)	<u>Testis</u>				
Female	1	2.9	nc	(nc-nc)	Male	4	1.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.5	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	6	6.8	87.9	(32.1-191.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	3.6	nc	(nc-nc)	Female	12	8.3	144.8	(74.7-253.0)
Female	4	2.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	113	130.3	86.7	(71.5-104.3)
Male	1	3.1	nc	(nc-nc)	Female	110	124.8	88.2	(72.5-106.3)
Female	1	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	14	17.1	82.1	(44.8-137.7)					
Female	12	17.2	69.8	(36.0-121.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	20.5	63.5	(33.8-108.6)	Male	17	12.4	137.5	(80.1-220.2)
Female	6	8.2	73.3	(26.8-159.6)	Female	13	10.5	123.7	(65.8-211.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.5	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	3	3.3	nc	(nc-nc)	Female	4	3.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.6	nc	(nc-nc)	Male	12	11.1	107.8	(55.6-188.3)
Female	94	78.2	120.2	(97.2-147.1)	Female	9	10.4	86.9	(39.6-164.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.6	nc	(nc-nc)	Male	5	7.6	66.2	(21.3-154.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	23.1	52.0	(26.8-90.9)	Female	7	7.3	95.2	(38.2-196.3)
Female	12	27.2	44.2	(22.8-77.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	6.4	nc	(nc-nc)
Male	5	5.1	98.7	(31.8-230.3)	Female	7	8.2	85.9	(34.4-176.9)
Female	2	1.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	95	70.6	134.5	(108.8-164.5)
Male	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.2	nc	(nc-nc)	Male	2	4.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	3.3	nc	(nc-nc)
Male	15	9.9	150.8	(84.4-248.8)	<u>Testis</u>				
Female	5	6.5	76.7	(24.7-179.0)	Male	3	1.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	2.9	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	7	12.5	56.2	(22.5-115.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	7.3	122.5	(55.9-232.5)	Female	11	17.9	61.6	(30.7-110.2)
Female	3	6.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	236	258.6	91.3	(80.0-103.7)
Male	2	5.8	nc	(nc-nc)	Female	247	279.1	88.5	(77.8-100.2)
Female	1	2.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	17	36.0	47.2	(27.5-75.6)					
Female	28	40.3	69.4	(46.1-100.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lowell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	78	82.7	94.3	(74.5-117.7)	Male	31	59.2	52.3	(35.5-74.3)
Female	47	32.3	145.5	(106.9-193.6)	Female	24	51.5	46.6	(29.9-69.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	19.0	68.3	(36.3-116.8)	Male	16	14.7	108.7	(62.1-176.5)
Female	18	16.7	108.1	(64.0-170.8)	Female	16	12.4	129.2	(73.8-209.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	5	2.6	190.2	(61.3-444.0)	Male	58	52.1	111.2	(84.5-143.8)
Female	272	347.3	78.3	(69.3-88.2)	Female	38	44.0	86.3	(61.1-118.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	16	14.5	110.5	(63.1-179.5)	Male	46	38.2	120.5	(88.2-160.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	117	100.5	116.4	(96.3-139.6)	Female	27	32.2	83.8	(55.2-121.9)
Female	103	107.2	96.1	(78.4-116.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	20	23.1	86.7	(53.0-134.0)	Male	22	27.4	80.3	(50.3-121.6)
Female	5	6.8	74.0	(23.8-172.6)	Female	25	31.9	78.4	(50.7-115.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	7	9.5	73.4	(29.4-151.3)	Male	257	332.1	77.4	(68.2-87.4)
Female	4	8.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	47	48.5	97.0	(71.2-129.0)	Male	19	19.9	95.5	(57.4-149.1)
Female	43	28.6	150.1	(108.6-202.2)	Female	16	12.9	124.2	(71.0-201.7)
<u>Larynx</u>					<u>Testis</u>				
Male	21	13.4	156.8	(97.0-239.7)	Male	13	16.8	77.4	(41.2-132.3)
Female	7	4.1	169.4	(67.9-349.0)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	38	33.8	112.4	(79.5-154.3)	Male	24	22.4	107.4	(68.8-159.8)
Female	42	27.4	153.3	(110.5-207.3)	Female	76	72.3	105.1	(82.8-131.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	59	27.5	214.4	(163.2-276.6)	Female	87	77.9	111.7	(89.4-137.8)
Female	11	9.5	116.2	(57.9-208.0)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	191	153.2	124.7	(107.6-143.7)	Male	1194	1185.6	100.7	(95.1-106.6)
Female	156	167.3	93.3	(79.2-109.1)	Female	1155	1218.8	94.8	(89.4-100.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ludlow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	26.9	100.2	(66.0-145.8)	Male	11	17.6	62.4	(31.1-111.6)
Female	8	9.2	87.4	(37.6-172.2)	Female	15	12.6	118.9	(66.5-196.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.0	138.8	(55.6-286.1)	Male	2	4.7	nc	(nc-nc)
Female	7	3.9	177.8	(71.2-366.3)	Female	3	3.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	10	15.5	64.4	(30.8-118.5)
Female	83	92.1	90.1	(71.7-111.7)	Female	8	11.9	67.2	(28.9-132.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.3	nc	(nc-nc)	Male	8	10.9	73.2	(31.5-144.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	39	31.6	123.6	(87.9-169.0)	Female	6	8.5	70.6	(25.8-153.6)
Female	26	29.8	87.3	(57.0-127.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	8.7	103.4	(47.2-196.3)
Male	6	7.0	85.2	(31.1-185.4)	Female	9	9.0	99.5	(45.4-188.9)
Female	1	1.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	98	101.4	96.7	(78.5-117.8)
Male	4	2.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.6	nc	(nc-nc)	Male	10	6.3	158.8	(76.0-292.1)
<u>Kidney & Renal Pelvis</u>					Female	3	3.6	nc	(nc-nc)
Male	11	14.2	77.3	(38.5-138.3)	<u>Testis</u>				
Female	4	7.7	nc	(nc-nc)	Male	6	3.8	157.2	(57.4-342.2)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	4.1	nc	(nc-nc)	Male	1	6.0	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	8	16.0	50.0	(21.5-98.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	10.0	90.3	(41.2-171.4)	Female	15	21.1	71.1	(39.7-117.2)
Female	4	6.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	328	361.6	90.7	(81.1-101.1)
Male	6	8.1	74.5	(27.2-162.2)	Female	257	324.9	79.1	(69.7-89.4)
Female	0	2.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	35	48.8	71.8	(50.0-99.8)					
Female	33	47.6	69.3	(47.7-97.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lunenburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	10.5	114.4	(59.0-199.9)	Male	9	7.4	122.3	(55.8-232.1)
Female	1	3.6	nc	(nc-nc)	Female	3	5.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.3	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
Female	3	1.7	nc	(nc-nc)	Female	4	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	6.4	nc	(nc-nc)
Female	40	42.3	94.5	(67.5-128.8)	Female	6	4.9	121.7	(44.4-264.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.6	nc	(nc-nc)	Male	3	4.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	13	12.8	101.6	(54.1-173.8)	Female	3	3.8	nc	(nc-nc)
Female	11	11.7	94.0	(46.9-168.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	3	3.0	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	3	0.7	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.9	nc	(nc-nc)	Male	55	42.7	128.9	(97.1-167.7)
Female	4	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	4	6.2	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
Female	1	3.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	1.7	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	6	4.1	146.0	(53.3-317.8)	Male	0	2.7	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)	Female	5	8.0	62.7	(20.2-146.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.6	nc	(nc-nc)	Female	14	9.8	143.2	(78.2-240.2)
Female	3	1.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	22	19.4	113.3	(71.0-171.6)	Male	157	149.3	105.2	(89.4-123.0)
Female	17	19.3	88.0	(51.2-140.9)	Female	132	140.4	94.0	(78.7-111.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lynn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	59	79.2	74.5	(56.7-96.1)	Male	45	54.6	82.5	(60.1-110.3)
Female	30	30.3	98.9	(66.7-141.2)	Female	27	46.9	57.6	(37.9-83.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	15	16.9	88.8	(49.7-146.5)	Male	17	14.0	121.7	(70.9-194.9)
Female	12	15.1	79.4	(41.0-138.8)	Female	10	11.6	85.9	(41.1-158.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	2.5	nc	(nc-nc)	Male	47	47.8	98.2	(72.2-130.7)
Female	304	323.8	93.9	(83.6-105.0)	Female	47	41.0	114.7	(84.2-152.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	12	13.0	92.2	(47.6-161.1)	Male	54	34.6	156.0	(117.2-203.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	92	94.1	97.7	(78.8-119.9)	Female	31	30.0	103.4	(70.3-146.8)
Female	97	100.0	97.0	(78.6-118.3)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	30	21.8	137.5	(92.8-196.3)	Male	24	26.0	92.1	(59.0-137.1)
Female	9	6.4	141.6	(64.6-268.8)	Female	28	29.9	93.5	(62.1-135.2)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	5	7.9	63.2	(20.4-147.4)	Male	17	18.8	90.5	(52.7-144.9)
Female	2	6.9	nc	(nc-nc)	Female	22	12.0	183.5	(114.9-277.8)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	46	44.7	102.8	(75.3-137.1)	Male	12	13.5	88.7	(45.8-154.9)
Female	29	26.8	108.4	(72.6-155.7)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	15	12.7	118.4	(66.2-195.3)	Female	80	73.4	109.0	(86.4-135.6)
Female	4	3.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	32	31.3	102.3	(69.9-144.4)	Male	1135	1115.1	101.8	(96.0-107.9)
Female	31	25.2	123.2	(83.7-174.8)	Female	1145	1133.7	101.0	(95.2-107.0)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	39	25.2	154.8	(110.0-211.6)					
Female	8	8.9	90.2	(38.8-177.7)					
<u>Lung and Bronchus</u>									
Male	175	147.2	118.9	(101.9-137.9)					
Female	173	158.0	109.5	(93.8-127.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lynnfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	15.6	102.4	(58.5-166.3)	Male	17	9.7	174.4	(101.5-279.2)
Female	7	5.3	131.4	(52.6-270.7)	Female	7	7.3	95.8	(38.4-197.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.7	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	13	8.6	150.3	(80.0-257.1)
Female	60	55.2	108.6	(82.9-139.9)	Female	9	7.0	129.5	(59.1-245.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.9	nc	(nc-nc)	Male	4	6.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	24	17.7	135.5	(86.8-201.7)	Female	9	5.0	178.5	(81.4-338.8)
Female	23	17.3	132.7	(84.1-199.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	5.0	nc	(nc-nc)
Male	1	4.0	nc	(nc-nc)	Female	5	5.3	95.2	(30.7-222.1)
Female	0	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	68	58.4	116.4	(90.4-147.6)
Male	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.9	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	2.1	nc	(nc-nc)
Male	11	8.0	138.0	(68.8-247.0)	<u>Testis</u>				
Female	6	4.6	131.7	(48.1-286.6)	Male	0	1.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	2.4	nc	(nc-nc)	Male	5	3.1	163.1	(52.6-380.7)
Female	0	0.7	nc	(nc-nc)	Female	15	9.2	163.3	(91.3-269.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	5.6	159.7	(72.9-303.2)	Female	15	12.8	117.6	(65.8-194.0)
Female	5	4.0	124.4	(40.1-290.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	221	205.0	107.8	(94.0-123.0)
Male	1	4.6	nc	(nc-nc)	Female	221	191.3	115.6	(100.8-131.8)
Female	2	1.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	29	28.7	101.1	(67.7-145.2)					
Female	28	27.9	100.4	(66.7-145.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Malden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	49	51.6	95.0	(70.3-125.6)	Male	15	36.1	41.5	(23.2-68.5)
Female	30	21.2	141.3	(95.3-201.7)	Female	23	32.7	70.3	(44.6-105.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	11.2	80.7	(36.8-153.2)	Male	9	9.1	98.7	(45.0-187.4)
Female	9	10.1	89.0	(40.6-168.9)	Female	7	8.1	86.2	(34.5-177.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.6	nc	(nc-nc)	Male	28	31.6	88.6	(58.8-128.0)
Female	202	224.3	90.1	(78.1-103.4)	Female	20	28.5	70.1	(42.8-108.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	9.2	87.2	(37.5-171.7)	Male	24	22.8	105.3	(67.4-156.7)
Female					Female	7	11.4	61.4	(24.6-126.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	94	62.1	151.4	(122.3-185.3)	Female	16	20.8	77.0	(44.0-125.0)
Female	82	69.9	117.4	(93.3-145.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	20	16.9	118.0	(72.1-182.3)
Male	19	14.1	135.1	(81.3-211.0)	Female	16	20.9	76.4	(43.6-124.1)
Female	5	4.4	112.5	(36.2-262.4)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	146	203.4	71.8	(60.6-84.4)
Male	6	5.6	107.8	(39.4-234.6)	<u>Stomach</u>				
Female	6	4.7	129.0	(47.1-280.7)	Male	17	12.3	138.2	(80.5-221.3)
<u>Kidney & Renal Pelvis</u>					Female	5	8.4	59.5	(19.2-138.9)
Male	35	29.3	119.6	(83.3-166.3)	<u>Testis</u>				
Female	19	18.6	102.4	(61.6-159.9)	Male	8	10.0	80.2	(34.5-158.1)
<u>Larynx</u>					<u>Thyroid</u>				
Male	12	8.2	146.5	(75.6-255.9)	Male	13	13.3	97.9	(52.1-167.5)
Female	5	2.7	184.5	(59.4-430.5)	Female	49	45.2	108.3	(80.1-143.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	23	20.2	113.7	(72.0-170.6)	Female	51	50.8	100.4	(74.8-132.0)
Female	18	17.0	105.8	(62.7-167.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	722	725.8	99.5	(92.4-107.0)
Male	29	16.6	174.2	(116.6-250.2)	Female	786	787.5	99.8	(92.9-107.0)
Female	9	6.1	146.7	(66.9-278.5)					
<u>Lung and Bronchus</u>									
Male	107	95.2	112.4	(92.1-135.8)					
Female	131	110.3	118.8	(99.3-140.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Manchester by the Sea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	7.1	nc	(nc-nc)	Male	14	4.4	315.7	(172.5-529.7)
Female	2	2.5	nc	(nc-nc)	Female	11	3.5	313.3	(156.2-560.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
Female	36	27.0	133.1	(93.2-184.3)	Female	4	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.9	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	8.2	97.5	(42.0-192.2)	Female	3	2.5	nc	(nc-nc)
Female	7	8.2	85.7	(34.3-176.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	4	1.8	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	33	26.0	126.7	(87.2-178.0)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	3.6	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	1.1	nc	(nc-nc)	Male	3	0.7	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	2	2.6	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	7	4.4	158.0	(63.3-325.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.1	nc	(nc-nc)	Female	6	6.4	93.8	(34.3-204.2)
Female	0	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	7	12.8	54.8	(22.0-112.9)	Male	101	93.0	108.7	(88.5-132.0)
Female	9	13.6	66.2	(30.2-125.7)	Female	112	92.6	121.0	(99.6-145.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mansfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	16.1	80.7	(42.9-138.0)	Male	19	12.5	152.3	(91.7-237.9)
Female	2	5.4	nc	(nc-nc)	Female	18	10.6	170.3	(100.9-269.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	4.3	nc	(nc-nc)	Male	0	3.0	nc	(nc-nc)
Female	7	3.3	212.5	(85.1-437.9)	Female	0	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	13	11.2	116.6	(62.0-199.4)
Female	82	73.3	111.8	(88.9-138.8)	Female	3	8.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.4	nc	(nc-nc)	Male	12	8.5	141.1	(72.8-246.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	23	21.2	108.5	(68.8-162.8)	Female	7	6.4	108.9	(43.6-224.4)
Female	24	18.9	127.0	(81.4-189.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	5.5	nc	(nc-nc)
Male	8	4.7	169.5	(73.0-334.0)	Female	10	5.3	187.3	(89.7-344.5)
Female	0	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	65	67.4	96.4	(74.4-122.9)
Male	0	2.0	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.6	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	2.2	nc	(nc-nc)
Male	10	10.6	94.6	(45.3-173.9)	<u>Testis</u>				
Female	13	5.5	235.3	(125.2-402.4)	Male	3	3.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	2.8	180.5	(58.2-421.2)	Male	9	5.1	175.1	(79.9-332.4)
Female	0	0.8	nc	(nc-nc)	Female	21	16.8	125.1	(77.4-191.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	7.2	125.5	(57.3-238.3)	Female	13	15.8	82.1	(43.7-140.4)
Female	4	5.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	241	244.5	98.6	(86.5-111.8)
Male	6	5.9	101.3	(37.0-220.5)	Female	272	237.4	114.6	(101.4-129.0)
Female	1	1.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	21	30.0	69.9	(43.2-106.8)					
Female	45	29.0	155.1	(113.1-207.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marblehead

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	24.7	72.8	(43.1-115.1)	Male	33	16.2	204.0	(140.4-286.6)
Female	16	9.1	175.1	(100.0-284.4)	Female	26	13.0	199.8	(130.5-292.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.7	107.5	(34.6-250.9)	Male	2	4.3	nc	(nc-nc)
Female	7	4.0	173.6	(69.5-357.6)	Female	3	3.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	18	14.1	127.2	(75.4-201.1)
Female	122	98.4	124.0	(103.0-148.1)	Female	10	12.1	82.8	(39.6-152.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.5	nc	(nc-nc)	Male	11	10.6	103.7	(51.7-185.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	29	29.0	99.9	(66.9-143.5)	Female	12	8.9	134.1	(69.2-234.3)
Female	25	29.8	83.9	(54.3-123.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	11	8.1	135.1	(67.4-241.8)
Male	3	6.8	nc	(nc-nc)	Female	9	9.0	100.3	(45.8-190.4)
Female	2	1.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	110	99.2	110.8	(91.1-133.6)
Male	0	1.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.5	nc	(nc-nc)	Male	2	5.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	3.5	nc	(nc-nc)
Male	11	13.6	81.2	(40.5-145.3)	<u>Testis</u>				
Female	6	8.0	75.1	(27.4-163.5)	Male	3	2.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	3.9	nc	(nc-nc)	Male	7	5.4	129.8	(52.0-267.5)
Female	0	1.2	nc	(nc-nc)	Female	13	16.9	76.8	(40.8-131.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	9.2	130.4	(67.3-227.8)	Female	15	22.8	65.7	(36.7-108.4)
Female	11	7.0	157.9	(78.7-282.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	346	339.1	102.0	(91.6-113.4)
Male	5	7.8	64.2	(20.7-149.9)	Female	377	335.9	112.2	(101.2-124.1)
Female	5	2.7	187.1	(60.3-436.6)					
<u>Lung and Bronchus</u>									
Male	30	45.7	65.7	(44.3-93.7)					
Female	45	48.0	93.8	(68.4-125.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marion

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	7.6	78.6	(28.7-171.1)	Male	6	4.7	128.7	(47.0-280.1)
Female	3	2.7	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
Female	38	26.4	143.8	(101.8-197.4)	Female	4	3.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	8.7	nc	(nc-nc)	Female	4	2.5	nc	(nc-nc)
Female	7	8.8	80.0	(32.0-164.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	4	2.0	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.5	nc	(nc-nc)	Female	33	29.0	113.7	(78.3-159.7)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	3.8	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	5	2.7	184.2	(59.4-429.8)	Female	3	4.2	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	2	2.2	nc	(nc-nc)	Male	4	6.2	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	9	13.7	65.6	(29.9-124.4)	Female	87	99.6	87.4	(70.0-107.7)
Female	12	13.9	86.3	(44.5-150.7)	Female	96	93.5	102.6	(83.1-125.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	46	34.6	132.8	(97.2-177.1)	Male	19	24.8	76.6	(46.1-119.6)
Female	14	13.6	102.9	(56.2-172.6)	Female	11	20.8	53.0	(26.4-94.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	7.6	79.0	(28.8-172.0)	Male	5	6.2	80.7	(26.0-188.4)
Female	6	6.5	92.7	(33.8-201.7)	Female	3	5.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	28	21.6	129.6	(86.1-187.3)
Female	120	145.4	82.5	(68.4-98.7)	Female	15	18.2	82.2	(46.0-135.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	12	5.9	204.2	(105.4-356.7)	Male	17	15.9	106.9	(62.2-171.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	32	42.3	75.7	(51.8-106.9)	Female	14	13.4	104.6	(57.1-175.5)
Female	47	45.2	104.0	(76.4-138.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	11.5	60.6	(24.3-124.9)
Male	11	9.6	114.7	(57.2-205.3)	Female	8	13.4	59.5	(25.6-117.3)
Female	6	2.8	212.0	(77.4-461.5)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	133	137.8	96.5	(80.8-114.4)
Male	8	3.5	226.1	(97.3-445.5)	<u>Stomach</u>				
Female	2	2.8	nc	(nc-nc)	Male	11	8.4	131.2	(65.4-234.7)
<u>Kidney & Renal Pelvis</u>					Female	5	5.4	91.8	(29.6-214.3)
Male	29	20.6	140.9	(94.4-202.4)	<u>Testis</u>				
Female	9	11.9	75.9	(34.7-144.2)	Male	6	6.4	94.1	(34.3-204.7)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	5.6	nc	(nc-nc)	Male	9	9.4	95.6	(43.6-181.5)
Female	2	1.7	nc	(nc-nc)	Female	39	28.7	136.0	(96.7-185.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	20	13.6	146.7	(89.6-226.6)	Female	37	32.7	113.2	(79.7-156.0)
Female	8	11.0	72.8	(31.4-143.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	499	493.0	101.2	(92.5-110.5)
Male	15	11.3	132.8	(74.3-219.0)	Female	500	505.7	98.9	(90.4-107.9)
Female	5	3.9	126.9	(40.9-296.1)					
<u>Lung and Bronchus</u>									
Male	58	64.4	90.0	(68.4-116.4)					
Female	79	69.7	113.4	(89.8-141.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marshfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	25.1	115.5	(77.3-165.9)	Male	35	18.0	194.8	(135.6-270.9)
Female	11	8.5	129.1	(64.3-231.0)	Female	21	13.9	151.1	(93.5-231.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	5.4	nc	(nc-nc)	Male	8	4.7	170.5	(73.4-336.0)
Female	5	4.3	115.9	(37.3-270.4)	Female	6	3.4	177.9	(65.0-387.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	0.8	nc	(nc-nc)	Male	17	15.5	109.8	(63.9-175.8)
Female	129	103.6	124.5	(103.9-147.9)	Female	16	11.9	134.2	(76.7-218.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	4.0	149.0	(54.4-324.4)	Male	10	12.3	81.6	(39.0-150.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	37	30.9	119.9	(84.4-165.3)	Female	14	9.2	151.4	(82.7-254.0)
Female	29	27.7	104.7	(70.1-150.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	8.6	81.6	(32.7-168.1)
Male	10	7.5	132.9	(63.6-244.4)	Female	8	8.3	96.6	(41.6-190.4)
Female	2	1.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	127	113.4	112.0	(93.4-133.3)
Male	5	2.2	228.4	(73.6-532.9)	<u>Stomach</u>				
Female	3	1.8	nc	(nc-nc)	Male	4	6.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	4	3.2	nc	(nc-nc)
Male	19	15.3	123.9	(74.6-193.5)	<u>Testis</u>				
Female	5	8.2	61.2	(19.7-142.7)	Male	4	3.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	4.4	nc	(nc-nc)	Male	2	6.6	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	22	19.8	110.9	(69.5-167.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	9.9	121.8	(62.9-212.8)	Female	23	24.2	95.2	(60.3-142.8)
Female	7	6.9	100.9	(40.4-207.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	420	373.1	112.6	(102.1-123.9)
Male	6	8.9	67.5	(24.7-147.0)	Female	421	341.5	123.3	(111.8-135.7)
Female	2	2.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	54	48.5	111.4	(83.7-145.4)					
Female	69	46.9	147.3	(114.6-186.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mashpee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	36	23.8	151.3	(105.9-209.4)	Male	21	14.2	148.0	(91.6-226.2)
Female	9	7.4	121.7	(55.5-231.0)	Female	11	9.7	113.8	(56.8-203.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.7	nc	(nc-nc)	Male	5	4.0	124.8	(40.2-291.4)
Female	3	3.1	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	14	12.4	112.6	(61.5-189.0)
Female	89	72.1	123.5	(99.2-152.0)	Female	11	9.5	115.8	(57.7-207.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.5	nc	(nc-nc)	Male	7	8.5	82.5	(33.0-170.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	27	26.3	102.8	(67.7-149.5)	Female	7	6.7	104.7	(42.0-215.8)
Female	28	23.3	119.9	(79.7-173.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	7.5	106.0	(45.6-208.9)
Male	5	6.0	83.5	(26.9-194.8)	Female	8	7.3	109.9	(47.3-216.6)
Female	0	1.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	101	86.5	116.8	(95.1-141.9)
Male	4	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.2	nc	(nc-nc)	Male	8	5.3	150.5	(64.8-296.6)
<u>Kidney & Renal Pelvis</u>					Female	2	2.8	nc	(nc-nc)
Male	17	11.4	148.7	(86.6-238.1)	<u>Testis</u>				
Female	9	6.2	144.8	(66.1-274.9)	Male	6	1.7	346.6	(126.6-754.4)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	3.4	nc	(nc-nc)	Male	1	4.2	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	10	11.8	85.0	(40.7-156.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	8.2	97.7	(42.1-192.5)	Female	17	16.9	100.6	(58.6-161.1)
Female	6	5.4	110.4	(40.3-240.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	333	302.0	110.3	(98.7-122.8)
Male	4	6.5	nc	(nc-nc)	Female	294	256.8	114.5	(101.8-128.4)
Female	4	2.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	35	43.1	81.2	(56.5-112.9)					
Female	50	39.5	126.5	(93.9-166.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mattapoisett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	10.8	92.9	(44.5-170.8)	Male	10	6.7	150.2	(71.9-276.2)
Female	4	3.1	nc	(nc-nc)	Female	7	4.2	167.2	(67.0-344.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.7	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.8	103.2	(37.7-224.6)
Female	32	32.0	99.9	(68.3-141.1)	Female	2	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.1	nc	(nc-nc)	Male	8	4.2	189.3	(81.5-373.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	12.2	nc	(nc-nc)	Female	6	2.9	205.1	(74.9-446.5)
Female	17	9.8	173.6	(101.1-278.0)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	2.8	nc	(nc-nc)	Male	46	41.1	111.9	(81.9-149.3)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	5.5	nc	(nc-nc)	Female	9	7.6	119.1	(54.4-226.2)
Female	0	2.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	1.6	nc	(nc-nc)	Male	5	3.7	135.7	(43.7-316.7)
Female	0	0.4	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	1	3.2	nc	(nc-nc)	Male	11	19.8	55.5	(27.7-99.4)
Female	0	0.9	nc	(nc-nc)	Female	12	16.3	73.4	(37.9-128.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Maynard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	11.0	109.3	(56.4-190.9)	Male	11	7.1	154.0	(76.8-275.5)
Female	2	3.9	nc	(nc-nc)	Female	11	6.0	184.1	(91.8-329.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.2	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	9	6.4	139.9	(63.8-265.6)
Female	47	43.0	109.2	(80.3-145.3)	Female	4	5.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.7	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	12.8	140.5	(83.2-222.0)	Female	3	3.9	nc	(nc-nc)
Female	17	12.8	133.3	(77.6-213.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	3.5	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	40	38.6	103.5	(74.0-141.0)
Male	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.8	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.5	nc	(nc-nc)
Male	4	5.8	nc	(nc-nc)	<u>Testis</u>				
Female	2	3.5	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.6	nc	(nc-nc)	Male	5	2.4	205.6	(66.3-479.9)
Female	1	0.5	nc	(nc-nc)	Female	10	8.3	120.4	(57.6-221.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	4.2	nc	(nc-nc)	Female	12	9.8	122.7	(63.3-214.3)
Female	2	3.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	149	144.5	103.1	(87.2-121.1)
Male	2	3.3	nc	(nc-nc)	Female	158	146.8	107.6	(91.5-125.8)
Female	3	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	19.6	66.3	(35.3-113.4)					
Female	19	20.3	93.4	(56.2-145.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	11.4	79.2	(36.2-150.4)	Male	14	7.9	177.0	(96.7-296.9)
Female	7	3.8	185.0	(74.1-381.2)	Female	9	6.3	143.9	(65.7-273.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.5	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	7.1	70.4	(22.7-164.3)
Female	63	47.1	133.6	(102.7-171.0)	Female	3	5.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.8	nc	(nc-nc)	Male	5	5.4	93.2	(30.0-217.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	20	14.2	141.3	(86.2-218.2)	Female	3	4.1	nc	(nc-nc)
Female	18	12.7	141.6	(83.9-223.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	2	3.2	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	53	45.7	116.0	(86.9-151.8)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	3	6.7	nc	(nc-nc)	Male	0	2.8	nc	(nc-nc)
Female	2	3.6	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	1.9	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	6	4.5	131.9	(48.2-287.1)	Male	3	2.9	nc	(nc-nc)
Female	7	3.2	218.1	(87.4-449.3)	Female	9	9.0	99.5	(45.4-188.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	3.9	nc	(nc-nc)	Female	13	10.6	122.8	(65.3-209.9)
Female	2	1.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	17	21.1	80.6	(46.9-129.1)	Male	162	161.8	100.1	(85.3-116.8)
Female	15	20.3	74.0	(41.4-122.0)	Female	171	153.5	111.4	(95.3-129.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	74	64.1	115.4	(90.6-144.8)	Male	39	40.1	97.3	(69.2-133.0)
Female	30	25.4	118.3	(79.8-168.9)	Female	32	34.6	92.4	(63.2-130.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	11.4	87.4	(41.8-160.8)	Male	5	10.7	46.5	(15.0-108.6)
Female	11	10.8	101.9	(50.8-182.4)	Female	13	9.5	136.4	(72.6-233.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	1.9	nc	(nc-nc)	Male	32	35.5	90.3	(61.7-127.4)
Female	252	241.5	104.3	(91.9-118.1)	Female	20	32.6	61.4	(37.5-94.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	11	9.0	122.4	(61.0-219.1)	Male	33	23.5	140.6	(96.8-197.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	89	72.3	123.1	(98.8-151.5)	Female	28	22.8	122.9	(81.7-177.7)
Female	75	83.0	90.4	(71.1-113.3)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	12	15.7	76.5	(39.5-133.6)	Male	20	20.2	99.1	(60.5-153.0)
Female	4	5.3	nc	(nc-nc)	Female	13	25.2	51.6	(27.5-88.3)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	7	5.4	130.2	(52.2-268.3)	Male	13	14.5	89.7	(47.7-153.4)
Female	4	4.7	nc	(nc-nc)	Female	9	10.1	89.1	(40.6-169.1)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	34	31.3	108.7	(75.3-152.0)	Male	7	9.2	76.3	(30.6-157.3)
Female	20	20.6	97.0	(59.2-149.8)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	9.0	133.3	(68.8-232.9)	Female	54	54.8	98.5	(74.0-128.6)
Female	1	3.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	26	23.3	111.6	(72.9-163.5)	Male	777	815.7	95.3	(88.7-102.2)
Female	23	19.2	119.7	(75.9-179.6)	Female	866	876.2	98.8	(92.4-105.6)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	17	17.7	95.8	(55.8-153.5)					
Female	11	7.1	155.8	(77.7-278.9)					
<u>Lung and Bronchus</u>									
Male	114	112.8	101.0	(83.3-121.4)					
Female	128	128.4	99.7	(83.2-118.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	11.7	94.3	(47.0-168.7)	Male	6	8.1	74.3	(27.1-161.7)
Female	2	3.9	nc	(nc-nc)	Female	6	6.6	91.3	(33.4-198.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.5	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	11	7.2	152.5	(76.0-273.0)
Female	35	47.6	73.6	(51.2-102.3)	Female	7	5.5	126.9	(50.8-261.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.9	nc	(nc-nc)	Male	5	5.4	92.4	(29.8-215.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	14.2	98.6	(53.9-165.5)	Female	4	4.2	nc	(nc-nc)
Female	18	13.5	133.7	(79.2-211.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	3.9	nc	(nc-nc)
Male	5	3.3	153.3	(49.4-357.9)	Female	3	3.9	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	55	46.6	118.0	(88.9-153.6)
Male	2	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.9	nc	(nc-nc)	Male	0	2.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.6	nc	(nc-nc)
Male	4	6.8	nc	(nc-nc)	<u>Testis</u>				
Female	1	3.7	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.9	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	8	9.5	83.9	(36.1-165.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	4.7	nc	(nc-nc)	Female	5	10.4	47.9	(15.4-111.7)
Female	3	3.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	160	164.8	97.1	(82.6-113.4)
Male	2	3.9	nc	(nc-nc)	Female	133	157.9	84.2	(70.5-99.8)
Female	0	1.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	19	21.3	89.0	(53.6-139.0)					
Female	25	20.7	120.8	(78.1-178.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Melrose

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	37	33.4	110.9	(78.1-152.8)	Male	27	20.9	129.4	(85.2-188.2)
Female	19	12.6	150.9	(90.8-235.6)	Female	22	17.2	127.7	(80.0-193.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	6.0	234.5	(128.1-393.5)	Male	2	5.7	nc	(nc-nc)
Female	5	5.4	92.9	(29.9-216.8)	Female	5	4.8	104.9	(33.8-244.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	20	18.5	108.2	(66.1-167.1)
Female	126	124.6	101.2	(84.3-120.4)	Female	15	16.3	92.2	(51.6-152.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	4.6	nc	(nc-nc)	Male	14	12.6	110.8	(60.5-186.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	36	38.3	94.0	(65.8-130.2)	Female	14	11.6	121.0	(66.1-203.0)
Female	46	41.4	111.0	(81.3-148.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	10.6	94.2	(45.1-173.2)
Male	5	8.3	60.1	(19.4-140.3)	Female	15	12.5	120.2	(67.2-198.3)
Female	5	2.6	189.8	(61.2-442.8)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	100	116.6	85.8	(69.8-104.3)
Male	2	2.4	nc	(nc-nc)	<u>Stomach</u>				
Female	3	2.1	nc	(nc-nc)	Male	7	7.6	91.6	(36.7-188.7)
<u>Kidney & Renal Pelvis</u>					Female	5	5.0	99.7	(32.1-232.6)
Male	20	16.7	119.8	(73.1-185.0)	<u>Testis</u>				
Female	11	10.4	105.6	(52.6-188.9)	Male	1	3.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	9	4.8	188.9	(86.2-358.6)	Male	10	6.7	148.3	(71.0-272.8)
Female	1	1.5	nc	(nc-nc)	Female	26	21.9	118.9	(77.7-174.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	15	12.3	122.0	(68.3-201.3)	Female	31	28.3	109.7	(74.5-155.7)
Female	6	9.6	62.6	(22.8-136.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	428	428.6	99.9	(90.6-109.8)
Male	5	9.4	53.4	(17.2-124.6)	Female	451	442.3	102.0	(92.8-111.8)
Female	2	3.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	65	58.9	110.3	(85.1-140.6)					
Female	56	63.9	87.6	(66.2-113.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	5.1	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	3.2	155.6	(50.1-363.1)
Female	26	21.3	121.9	(79.6-178.6)	Female	5	2.4	212.6	(68.5-496.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.9	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	6.6	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
Female	6	5.5	108.6	(39.7-236.5)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	1.5	nc	(nc-nc)	Male	38	22.2	171.4	(121.2-235.2)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	3.1	nc	(nc-nc)	Female	3	4.8	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.9	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	1	1.8	nc	(nc-nc)	Male	6	9.5	63.4	(23.1-137.9)
Female	0	0.5	nc	(nc-nc)	Female	7	8.8	79.2	(31.7-163.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Merrimac

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	7.1	84.5	(30.9-183.9)	Male	4	4.8	nc	(nc-nc)
Female	5	2.2	228.4	(73.6-533.0)	Female	5	3.5	141.7	(45.7-330.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.4	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
Female	24	26.3	91.3	(58.5-135.8)	Female	3	3.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	0	3.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	8.5	70.7	(25.8-153.9)	Female	4	2.3	nc	(nc-nc)
Female	7	7.2	97.2	(38.9-200.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	2.4	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	27	28.9	93.3	(61.5-135.8)
Male	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	0.8	nc	(nc-nc)
Male	4	4.1	nc	(nc-nc)	<u>Testis</u>				
Female	5	2.1	241.3	(77.7-563.0)	Male	1	0.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	1.2	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	5.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	2.7	nc	(nc-nc)	Female	6	6.0	100.2	(36.6-218.1)
Female	1	1.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	90	99.8	90.2	(72.5-110.9)
Male	1	2.3	nc	(nc-nc)	Female	85	86.9	97.8	(78.1-120.9)
Female	0	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	13.2	98.5	(52.4-168.4)					
Female	14	11.9	117.3	(64.1-196.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Methuen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	52	42.7	121.7	(90.9-159.5)	Male	21	28.6	73.4	(45.4-112.2)
Female	20	19.1	104.5	(63.8-161.3)	Female	26	27.1	95.9	(62.6-140.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	8.7	92.3	(39.7-181.8)	Male	7	7.4	94.1	(37.7-193.8)
Female	10	8.6	116.7	(55.9-214.6)	Female	4	7.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.3	nc	(nc-nc)	Male	22	25.4	86.7	(54.3-131.3)
Female	206	192.9	106.8	(92.7-122.4)	Female	21	25.0	83.9	(51.9-128.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	7.3	123.7	(56.5-234.9)	Male	15	18.2	82.6	(46.2-136.2)
<u>Colon / Rectum</u>					Female	10	9.9	100.9	(48.3-185.6)
Male	65	50.9	127.6	(98.5-162.6)	<u>Ovary</u>				
Female	64	63.3	101.2	(77.9-129.2)	Female	10	17.9	55.9	(26.7-102.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	11.3	124.2	(67.9-208.5)	Male	23	13.9	165.3	(104.8-248.1)
Female	1	4.0	nc	(nc-nc)	Female	16	19.0	84.3	(48.2-136.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	3.8	nc	(nc-nc)	Male	184	159.1	115.7	(99.5-133.6)
Female	2	3.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	10.1	99.3	(47.5-182.6)
Male	26	23.3	111.4	(72.8-163.3)	Female	9	7.7	117.6	(53.7-223.3)
Female	16	16.1	99.6	(56.9-161.7)	<u>Testis</u>				
<u>Larynx</u>					Male	9	6.2	144.6	(66.0-274.4)
Male	9	6.5	138.3	(63.1-262.5)	<u>Thyroid</u>				
Female	2	2.3	nc	(nc-nc)	Male	9	10.0	89.6	(40.9-170.1)
<u>Leukemia</u>					Female	34	35.2	96.5	(66.8-134.9)
Male	15	16.5	90.8	(50.8-149.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	14	15.0	93.5	(51.1-156.9)	Female	42	43.4	96.7	(69.7-130.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	15	13.2	113.2	(63.3-186.8)	Male	634	579.3	109.4	(101.1-118.3)
Female	3	5.4	nc	(nc-nc)	Female	691	683.0	101.2	(93.8-109.0)
<u>Lung and Bronchus</u>									
Male	85	77.1	110.2	(88.0-136.3)					
Female	102	97.5	104.7	(85.3-127.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	31	17.5	176.6	(120.0-250.7)	Male	24	12.4	193.4	(123.9-287.8)
Female	15	8.0	187.2	(104.7-308.8)	Female	16	12.3	130.4	(74.5-211.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	4.0	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
Female	2	3.8	nc	(nc-nc)	Female	6	3.1	193.9	(70.8-422.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.6	nc	(nc-nc)	Male	17	11.1	153.7	(89.5-246.1)
Female	90	88.4	101.8	(81.9-125.2)	Female	8	10.8	73.8	(31.8-145.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	3.4	145.4	(46.9-339.4)	Male	6	8.4	71.4	(26.1-155.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	36	21.4	168.4	(117.9-233.1)	Female	13	8.1	161.0	(85.7-275.4)
Female	31	26.3	118.1	(80.2-167.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	5.9	153.2	(69.9-290.8)
Male	12	5.1	236.8	(122.2-413.6)	Female	9	7.9	114.4	(52.2-217.1)
Female	2	1.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	91	74.3	122.5	(98.6-150.4)
Male	2	1.9	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.7	nc	(nc-nc)	Male	9	4.3	210.9	(96.3-400.5)
<u>Kidney & Renal Pelvis</u>					Female	1	3.1	nc	(nc-nc)
Male	20	10.4	192.7	(117.7-297.7)	<u>Testis</u>				
Female	4	7.2	nc	(nc-nc)	Male	6	2.9	208.1	(76.0-453.0)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.9	nc	(nc-nc)	Male	6	4.6	131.1	(47.9-285.4)
Female	1	1.1	nc	(nc-nc)	Female	16	16.9	94.9	(54.2-154.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	14	7.2	194.8	(106.4-326.9)	Female	26	20.2	128.5	(83.9-188.2)
Female	10	6.4	155.8	(74.6-286.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	369	255.4	144.5	(130.1-160.0)
Male	6	6.0	99.8	(36.4-217.2)	Female	350	302.6	115.7	(103.9-128.4)
Female	5	2.4	212.7	(68.5-496.4)					
<u>Lung and Bronchus</u>									
Male	45	32.7	137.7	(100.4-184.2)					
Female	61	42.3	144.4	(110.4-185.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middlefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	1	2.4	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	5	7.7	64.7	(20.8-150.9)
Male	0	0.2	nc	(nc-nc)	Female	5	7.3	68.4	(22.1-159.7)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	1.0	nc	(nc-nc)					
Female	0	1.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	7.7	129.1	(61.8-237.5)	Male	7	5.9	117.8	(47.2-242.6)
Female	4	2.9	nc	(nc-nc)	Female	7	4.3	160.9	(64.5-331.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.8	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	5.1	136.2	(54.6-280.7)
Female	40	32.4	123.3	(88.1-167.9)	Female	5	3.9	128.9	(41.5-300.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.2	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	9	9.9	91.3	(41.6-173.3)	Female	1	2.9	nc	(nc-nc)
Female	8	9.3	86.1	(37.1-169.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	2.7	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	40	33.1	120.9	(86.3-164.6)
Male	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.5	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.1	nc	(nc-nc)
Male	3	5.0	nc	(nc-nc)	<u>Testis</u>				
Female	4	2.6	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.3	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	7	6.0	117.5	(47.1-242.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.2	nc	(nc-nc)	Female	5	7.4	67.5	(21.7-157.4)
Female	4	2.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	135	116.5	115.9	(97.2-137.2)
Male	6	2.8	217.0	(79.2-472.3)	Female	131	109.3	119.9	(100.3-142.3)
Female	1	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	16	14.7	109.0	(62.2-177.0)					
Female	24	15.5	155.2	(99.4-231.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Milford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	49	23.5	208.4	(154.2-275.6)	Male	11	16.9	65.2	(32.5-116.7)
Female	9	10.3	87.0	(39.7-165.2)	Female	8	15.5	51.6	(22.2-101.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	5.3	nc	(nc-nc)	Male	6	4.2	141.8	(51.8-308.7)
Female	4	4.9	nc	(nc-nc)	Female	6	4.0	151.7	(55.4-330.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	15	14.9	100.7	(56.3-166.1)
Female	79	109.3	72.3	(57.2-90.1)	Female	21	13.8	152.4	(94.3-233.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	4.3	139.1	(50.8-302.8)	Male	8	11.1	71.9	(31.0-141.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	36	29.2	123.4	(86.4-170.8)	Female	7	10.1	69.4	(27.8-142.9)
Female	35	34.5	101.6	(70.7-141.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	7.8	115.4	(52.6-219.0)
Male	7	6.7	105.3	(42.2-216.9)	Female	9	10.2	88.0	(40.2-167.1)
Female	1	2.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	139	96.2	144.5	(121.4-170.6)
Male	5	2.5	200.1	(64.5-466.9)	<u>Stomach</u>				
Female	0	2.1	nc	(nc-nc)	Male	11	5.8	190.9	(95.1-341.5)
<u>Kidney & Renal Pelvis</u>					Female	2	4.1	nc	(nc-nc)
Male	18	14.0	128.4	(76.0-202.9)	<u>Testis</u>				
Female	7	8.9	78.5	(31.5-161.8)	Male	4	4.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	3.9	nc	(nc-nc)	Male	4	6.4	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	18	21.0	85.5	(50.7-135.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	9.5	115.2	(57.4-206.2)	Female	19	24.6	77.1	(46.4-120.4)
Female	9	8.3	108.5	(49.5-206.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	420	340.0	123.5	(112.0-135.9)
Male	3	8.0	nc	(nc-nc)	Female	328	380.9	86.1	(77.0-95.9)
Female	1	3.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	54	43.6	123.9	(93.0-161.6)					
Female	56	52.6	106.4	(80.4-138.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	14.4	138.7	(84.7-214.2)	Male	8	9.7	82.6	(35.6-162.9)
Female	13	5.9	220.6	(117.4-377.3)	Female	3	8.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	2.8	178.4	(57.5-416.2)	Male	4	2.5	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	12	8.5	141.3	(72.9-246.9)
Female	52	59.5	87.4	(65.3-114.6)	Female	3	7.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.2	nc	(nc-nc)	Male	6	6.3	94.9	(34.7-206.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	17	17.0	99.7	(58.1-159.7)	Female	6	5.5	108.6	(39.7-236.4)
Female	17	19.3	87.9	(51.2-140.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	4.7	nc	(nc-nc)
Male	5	4.0	126.5	(40.8-295.3)	Female	13	5.8	222.9	(118.6-381.1)
Female	2	1.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	58	57.1	101.7	(77.2-131.4)
Male	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.0	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	2.3	nc	(nc-nc)
Male	15	8.0	187.9	(105.1-310.0)	<u>Testis</u>				
Female	9	5.0	181.5	(82.8-344.5)	Male	3	1.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	2.3	218.4	(70.4-509.7)	Male	4	3.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	8	10.6	75.3	(32.4-148.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	5.4	nc	(nc-nc)	Female	14	13.6	103.1	(56.3-173.0)
Female	5	4.5	110.7	(35.7-258.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	221	198.8	111.1	(97.0-126.8)
Male	4	4.6	nc	(nc-nc)	Female	223	209.9	106.2	(92.7-121.1)
Female	2	1.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	30	26.5	113.4	(76.5-161.8)					
Female	39	30.2	129.0	(91.7-176.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	6.5	138.4	(63.2-262.7)	Male	7	5.0	140.7	(56.4-289.9)
Female	2	2.5	nc	(nc-nc)	Female	7	4.3	163.5	(65.5-337.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.5	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
Female	38	31.7	120.1	(84.9-164.8)	Female	2	3.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.3	nc	(nc-nc)	Male	6	3.4	174.5	(63.7-379.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	8.4	166.0	(90.7-278.5)	Female	2	2.8	nc	(nc-nc)
Female	11	8.3	132.8	(66.2-237.5)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	2.0	nc	(nc-nc)	Male	32	29.9	106.9	(73.1-150.9)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	4.3	nc	(nc-nc)	Female	4	7.2	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	1.2	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	6	2.1	284.8	(104.0-619.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	3	2.5	nc	(nc-nc)	Male	13	12.7	102.2	(54.4-174.8)
Female	0	0.8	nc	(nc-nc)	Female	14	13.9	100.8	(55.1-169.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.1	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	5	9.9	50.3	(16.2-117.4)	Female	2	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	2.7	182.5	(58.8-426.0)	Female	0	0.9	nc	(nc-nc)
Female	0	2.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.7	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	11	8.8	124.6	(62.1-222.9)
Male	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.3	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.8	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.9	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	31	31.3	99.1	(67.3-140.6)
Male	0	0.7	nc	(nc-nc)	Female	26	32.8	79.3	(51.8-116.2)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	3.7	nc	(nc-nc)					
Female	8	4.2	188.9	(81.3-372.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Milton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	28	30.5	91.9	(61.1-132.9)	Male	35	19.2	182.1	(126.8-253.3)
Female	4	12.1	nc	(nc-nc)	Female	23	16.4	140.3	(88.9-210.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	5.6	nc	(nc-nc)	Male	8	5.2	154.4	(66.5-304.2)
Female	6	5.2	115.2	(42.1-250.7)	Female	9	4.6	196.6	(89.7-373.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.9	nc	(nc-nc)	Male	12	17.3	69.6	(35.9-121.5)
Female	115	119.6	96.2	(79.4-115.4)	Female	17	15.6	109.0	(63.5-174.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	4.3	117.3	(37.8-273.8)	Male	9	12.2	73.8	(33.7-140.1)
<u>Colon / Rectum</u>					Female	3	6.2	nc	(nc-nc)
Male	32	35.5	90.0	(61.6-127.1)	<u>Ovary</u>				
Female	41	40.0	102.5	(73.5-139.1)	Female	16	11.1	144.3	(82.4-234.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	7.8	63.7	(20.5-148.7)	Male	10	9.8	102.5	(49.1-188.5)
Female	4	2.5	nc	(nc-nc)	Female	10	12.0	83.3	(39.9-153.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	2.2	nc	(nc-nc)	Male	129	110.9	116.3	(97.1-138.2)
Female	2	2.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	7.1	nc	(nc-nc)
Male	15	15.7	95.6	(53.4-157.6)	Female	4	4.8	nc	(nc-nc)
Female	9	10.0	90.4	(41.3-171.6)	<u>Testis</u>				
<u>Larynx</u>					Male	6	3.2	188.2	(68.7-409.7)
Male	3	4.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.4	nc	(nc-nc)	Male	13	6.2	208.7	(111.0-356.8)
<u>Leukemia</u>					Female	25	20.5	122.1	(79.0-180.3)
Male	12	11.4	105.2	(54.3-183.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	9.3	96.9	(44.2-184.0)	Female	35	26.9	130.0	(90.5-180.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	9.1	66.0	(24.1-143.7)	Male	391	400.2	97.7	(88.3-107.9)
Female	3	3.4	nc	(nc-nc)	Female	425	423.6	100.3	(91.0-110.3)
<u>Lung and Bronchus</u>									
Male	33	54.4	60.7	(41.8-85.2)					
Female	57	61.0	93.5	(70.8-121.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monroe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
					Female	0	0.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	3	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	9.3	64.3	(23.5-140.0)	Male	11	6.6	165.6	(82.5-296.3)
Female	4	3.0	nc	(nc-nc)	Female	4	4.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	2.0	249.1	(80.3-581.3)	Male	1	1.7	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.9	nc	(nc-nc)
Female	29	35.6	81.5	(54.6-117.1)	Female	1	4.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.4	nc	(nc-nc)	Male	7	4.6	152.5	(61.1-314.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	11.6	68.8	(29.6-135.6)	Female	2	3.2	nc	(nc-nc)
Female	11	10.0	109.8	(54.8-196.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	3.1	222.3	(89.0-458.0)
Male	2	2.7	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	37	40.2	92.1	(64.8-126.9)
Male	3	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.6	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.2	nc	(nc-nc)
Male	4	5.7	nc	(nc-nc)	<u>Testis</u>				
Female	2	2.8	nc	(nc-nc)	Male	4	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.6	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	6.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	3.7	136.9	(44.1-319.5)	Female	6	8.2	73.3	(26.8-159.6)
Female	3	2.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	130	136.6	95.2	(79.5-113.0)
Male	3	3.2	nc	(nc-nc)	Female	102	118.8	85.9	(70.0-104.3)
Female	0	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	11	17.5	63.0	(31.4-112.8)					
Female	17	16.2	105.0	(61.1-168.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Montague

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	10.7	74.4	(32.0-146.7)	Male	4	6.9	nc	(nc-nc)
Female	4	3.8	nc	(nc-nc)	Female	2	5.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.9	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	6.1	nc	(nc-nc)
Female	39	38.2	102.0	(72.5-139.5)	Female	2	5.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	0	4.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	13	12.6	103.3	(54.9-176.6)	Female	5	3.6	140.4	(45.3-327.7)
Female	10	12.5	80.1	(38.3-147.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	3.5	nc	(nc-nc)
Male	6	2.9	207.8	(75.9-452.4)	Female	3	3.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	28	41.5	67.4	(44.8-97.4)
Male	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.7	nc	(nc-nc)	Male	5	2.5	198.7	(64.0-463.7)
<u>Kidney & Renal Pelvis</u>					Female	0	1.5	nc	(nc-nc)
Male	6	5.7	105.4	(38.5-229.4)	<u>Testis</u>				
Female	3	3.2	nc	(nc-nc)	Male	3	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.7	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	6.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	3.9	153.4	(56.0-333.9)	Female	11	8.8	124.3	(62.0-222.5)
Female	2	2.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	117	144.8	80.8	(66.8-96.8)
Male	0	3.4	nc	(nc-nc)	Female	113	135.6	83.3	(68.7-100.2)
Female	0	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	21	19.4	108.0	(66.8-165.1)					
Female	18	19.8	90.8	(53.8-143.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monterey

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.4	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	3	5.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	1.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	6.2	97.4	(35.6-212.0)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.8	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.2	nc	(nc-nc)	Male	15	19.4	77.2	(43.2-127.4)
Female	0	0.1	nc	(nc-nc)	Female	9	17.0	52.9	(24.1-100.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	0	0.3	nc	(nc-nc)	Male	15	19.4	77.2	(43.2-127.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Female	9	17.0	52.9	(24.1-100.4)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.7	nc	(nc-nc)	Male	15	19.4	77.2	(43.2-127.4)
Female	1	2.6	nc	(nc-nc)	Female	9	17.0	52.9	(24.1-100.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Montgomery

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.7	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	2	3.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	3.4	175.2	(64.0-381.4)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	0.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	1.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mount Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.1	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Nahant

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	6.4	124.4	(53.6-245.1)	Male	13	3.9	331.4	(176.3-566.8)
Female	4	1.9	nc	(nc-nc)	Female	0	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	3.4	144.9	(46.7-338.2)
Female	22	19.2	114.6	(71.8-173.5)	Female	0	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	7.3	nc	(nc-nc)	Female	4	1.8	nc	(nc-nc)
Female	6	6.3	94.8	(34.6-206.4)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	1.7	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	0	3.2	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.0	nc	(nc-nc)	Female	2	4.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	2.2	nc	(nc-nc)	Male	78	84.4	92.4	(73.0-115.3)
Female	2	1.4	nc	(nc-nc)	Female	65	67.3	96.6	(74.6-123.2)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	3	1.9	nc	(nc-nc)					
Female	2	0.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	9	11.7	77.0	(35.1-146.2)					
Female	10	9.8	102.2	(48.9-188.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Nantucket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	9.9	100.7	(48.2-185.2)	Male	23	7.2	318.0	(201.5-477.2)
Female	4	3.2	nc	(nc-nc)	Female	11	5.3	208.5	(103.9-373.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.2	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	6.3	110.8	(44.4-228.4)
Female	49	36.7	133.7	(98.9-176.7)	Female	4	4.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.6	nc	(nc-nc)	Male	6	4.8	125.1	(45.7-272.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	12.3	146.8	(87.0-232.1)	Female	7	3.3	210.2	(84.2-433.1)
Female	15	10.6	141.7	(79.3-233.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	3.3	150.5	(48.5-351.1)
Male	4	2.9	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
Female	4	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	72	42.0	171.5	(134.2-216.0)
Male	2	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.7	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.3	nc	(nc-nc)
Male	2	6.0	nc	(nc-nc)	<u>Testis</u>				
Female	2	3.0	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.7	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	3	7.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	4.0	nc	(nc-nc)	Female	9	8.3	108.9	(49.7-206.8)
Female	2	2.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	189	145.4	130.0	(112.1-149.9)
Male	0	3.4	nc	(nc-nc)	Female	148	125.1	118.3	(100.0-139.0)
Female	0	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	18.5	70.2	(37.3-120.0)					
Female	16	17.1	93.6	(53.5-152.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Natick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	35.6	98.4	(68.5-136.9)	Male	27	23.1	116.8	(76.9-169.9)
Female	16	13.4	119.3	(68.1-193.7)	Female	18	19.7	91.5	(54.2-144.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	17	6.8	248.3	(144.5-397.5)	Male	6	6.1	98.6	(36.0-214.6)
Female	8	6.1	130.7	(56.3-257.5)	Female	4	5.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	16	20.6	77.8	(44.5-126.4)
Female	161	141.9	113.5	(96.6-132.4)	Female	16	17.8	89.9	(51.3-146.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	5.5	nc	(nc-nc)	Male	12	14.6	82.0	(42.3-143.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	47	41.8	112.4	(82.6-149.4)	Female	15	13.0	115.5	(64.6-190.5)
Female	39	44.1	88.4	(62.9-120.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	12	11.5	104.5	(53.9-182.5)
Male	5	9.3	53.7	(17.3-125.4)	Female	14	13.2	105.7	(57.7-177.3)
Female	1	2.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	142	132.3	107.3	(90.4-126.5)
Male	1	2.9	nc	(nc-nc)	<u>Stomach</u>				
Female	3	2.5	nc	(nc-nc)	Male	11	8.4	131.7	(65.7-235.7)
<u>Kidney & Renal Pelvis</u>					Female	4	5.3	nc	(nc-nc)
Male	20	18.8	106.5	(65.0-164.5)	<u>Testis</u>				
Female	9	11.7	77.1	(35.2-146.4)	Male	0	4.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	5.4	nc	(nc-nc)	Male	13	7.9	165.6	(88.1-283.2)
Female	1	1.7	nc	(nc-nc)	Female	25	26.3	94.9	(61.4-140.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	13.6	73.6	(35.2-135.4)	Female	26	32.2	80.8	(52.8-118.4)
Female	13	10.5	123.3	(65.6-210.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	488	475.8	102.6	(93.7-112.1)
Male	5	10.7	46.9	(15.1-109.5)	Female	496	492.6	100.7	(92.0-110.0)
Female	0	3.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	58	63.5	91.4	(69.4-118.2)					
Female	62	69.8	88.8	(68.1-113.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Needham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	38	35.4	107.3	(75.9-147.3)	Male	36	21.6	167.0	(116.9-231.2)
Female	12	14.1	84.9	(43.8-148.2)	Female	19	18.3	103.8	(62.4-162.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	6.2	nc	(nc-nc)	Male	8	6.0	134.3	(57.8-264.6)
Female	6	5.8	102.7	(37.5-223.5)	Female	2	5.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	27	19.5	138.2	(91.1-201.1)
Female	161	135.0	119.2	(101.5-139.2)	Female	22	17.9	122.8	(76.9-185.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.7	nc	(nc-nc)	Male	14	13.2	105.7	(57.8-177.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	34	40.8	83.4	(57.7-116.5)	Female	7	12.7	55.3	(22.2-114.0)
Female	38	47.2	80.6	(57.0-110.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	12	11.1	107.7	(55.6-188.1)
Male	6	8.7	69.2	(25.3-150.7)	Female	20	14.1	141.7	(86.5-218.9)
Female	3	2.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	151	118.7	127.2	(107.7-149.2)
Male	4	2.3	nc	(nc-nc)	<u>Stomach</u>				
Female	3	2.1	nc	(nc-nc)	Male	6	8.1	74.0	(27.0-161.0)
<u>Kidney & Renal Pelvis</u>					Female	3	5.8	nc	(nc-nc)
Male	12	17.3	69.6	(35.9-121.5)	<u>Testis</u>				
Female	5	11.3	44.4	(14.3-103.6)	Male	5	3.4	148.2	(47.8-345.9)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	5.0	120.9	(44.2-263.2)	Male	13	6.8	191.7	(102.0-327.9)
Female	2	1.6	nc	(nc-nc)	Female	37	22.1	167.8	(118.1-231.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	13.2	60.8	(26.2-119.9)	Female	32	30.3	105.4	(72.1-148.9)
Female	12	10.8	111.6	(57.6-195.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	461	446.1	103.3	(94.1-113.2)
Male	5	9.9	50.4	(16.2-117.6)	Female	479	483.1	99.2	(90.5-108.5)
Female	1	3.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	39	61.2	63.7	(45.3-87.1)					
Female	52	69.4	75.0	(56.0-98.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Ashford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Female</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	5.6	89.0	(28.7-207.8)
Female	0	0.0	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Male</u>				
Male	0	0.1	nc	(nc-nc)	<u>Female</u>				
Female	0	0.1	nc	(nc-nc)	<u>Male</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Female</u>				
Male	0	0.1	nc	(nc-nc)	<u>Male</u>				
Female	0	0.0	nc	(nc-nc)	<u>Female</u>				
<u>Lung and Bronchus</u>					<u>Male</u>				
Male	0	0.7	nc	(nc-nc)	<u>Female</u>				
Female	0	0.5	nc	(nc-nc)	<u>Male</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	111	91.2	121.8	(100.2-146.6)	Male	40	58.9	67.9	(48.5-92.4)
Female	40	41.0	97.5	(69.6-132.7)	Female	24	56.0	42.9	(27.5-63.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	16	17.8	90.0	(51.4-146.1)	Male	18	15.5	116.0	(68.7-183.4)
Female	26	17.9	145.0	(94.7-212.5)	Female	14	15.4	90.9	(49.7-152.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	2.8	nc	(nc-nc)	Male	55	52.2	105.3	(79.3-137.1)
Female	329	389.6	84.5	(75.6-94.1)	Female	39	52.7	74.0	(52.6-101.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	26	14.5	179.4	(117.2-262.9)	Male	56	36.0	155.5	(117.4-201.9)
Female					Female	38	20.5	185.0	(130.9-253.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	127	105.0	120.9	(100.8-143.9)	Female	23	36.9	62.4	(39.5-93.6)
Female	126	134.8	93.4	(77.8-111.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	33	29.3	112.8	(77.6-158.4)
Male	37	23.4	158.2	(111.3-218.0)	Female	51	40.8	125.1	(93.1-164.4)
Female	7	8.6	81.6	(32.7-168.1)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	409	331.3	123.5	(111.8-136.0)
Male	10	8.0	125.6	(60.1-231.0)	<u>Stomach</u>				
Female	6	7.6	78.6	(28.7-171.1)	Male	31	21.0	147.5	(100.2-209.3)
<u>Kidney & Renal Pelvis</u>					Female	20	16.4	121.6	(74.2-187.8)
Male	68	47.3	143.9	(111.7-182.4)	<u>Testis</u>				
Female	36	33.3	108.2	(75.8-149.8)	Male	9	13.2	68.2	(31.1-129.4)
<u>Larynx</u>					<u>Thyroid</u>				
Male	17	13.5	126.3	(73.6-202.3)	Male	19	19.8	95.8	(57.7-149.6)
Female	15	4.8	314.3	(175.8-518.4)	Female	51	70.3	72.5	(54.0-95.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	38	34.7	109.5	(77.5-150.4)	Female	90	88.2	102.0	(82.0-125.4)
Female	27	31.8	84.8	(55.9-123.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	1487	1205.5	123.4	(117.2-129.8)
Male	54	26.7	202.2	(151.9-263.9)	Female	1323	1416.7	93.4	(88.4-98.6)
Female	12	11.4	105.0	(54.2-183.4)					
<u>Lung and Bronchus</u>									
Male	232	163.5	141.9	(124.2-161.4)					
Female	199	206.0	96.6	(83.6-111.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	2	4.0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	1.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	4.4	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.6	nc	(nc-nc)	Female	3	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Male</u>				
Male	0	0.2	nc	(nc-nc)	6	14.0	42.8	(15.6-93.1)	
Female	0	0.0	nc	(nc-nc)	<u>Female</u>				
<u>Leukemia</u>					11				
Male	0	0.4	nc	(nc-nc)	13.1	83.7	(41.7-149.8)		
Female	0	0.3	nc	(nc-nc)					
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	1	0.4	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	1.7	nc	(nc-nc)					
Female	1	1.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.4	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	6	7.0	85.6	(31.3-186.4)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	2.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.8	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	13	8.6	150.6	(80.1-257.6)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	0.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.9	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	31	30.8	100.8	(68.5-143.1)
Male	0	0.7	nc	(nc-nc)	Female	15	24.1	62.3	(34.9-102.8)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	2	4.1	nc	(nc-nc)					
Female	1	3.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	2	4.2	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	1.2	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.3	116.2	(37.4-271.1)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.6	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;